<DOC>
	<DOCNO>NCT02961556</DOCNO>
	<brief_summary>This baseline-controlled , open-label , multicenter study evaluate efficacy safety AJG555 orally administer 2 week pediatric participant chronic constipation . The safety efficacy 12 week administration also evaluate .</brief_summary>
	<brief_title>General Clinical Study AJG555 Pediatric Patients With Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Main Participants chronic constipation Age : 2 year old old 14 year old young ( time inform consent ) Gender : N/A Main Participants organic constipation participant suspect organic constipation Participants symptomatic constipation participant suspect symptomatic constipation Participants druginduced constipation participant suspect druginduced constipation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AJG555</keyword>
	<keyword>Constipation</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Pediatric participant</keyword>
</DOC>